Dr. Shah on Results Seen With Brexucabtagene Autoleucel in Relapsed/Refractory B-ALL

Bijal Shah, MD, MS, an associate member in the Department of Malignant Hematology at Moffitt Cancer Center, discusses the results seen with brexucabtagne autoleucel (formerly KTE-X19; Tecartus) in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL), as demonstrated in the phase 2 ZUMA-3 trial (NCT02614066).

Results from the trial demonstrated that the agent yielded a complete remission (CR) rate of approximately 56%, according to Shah. Additionally, these CRs translated into improvements in relapse-free survival, overall survival (OS), and duration of remission, which were well beyond the expectations of investigators, Shah says.

Moreover, in patients who achieved a CR/CR with incomplete blood count recovery (CRi), the median OS still has not been met, Shah adds. In this patient population, these results are quite remarkable, Shah concludes.